VEGFA and cardiomyopathy: ILK adenoviral gene therapy has been shown to improve remodeling in a rat MI model through upregulation of vascular endothelial growth factor-mediated angiogenesis[24], and to protect against adverse remodeling in chronic DOX-induced cardiomyopathy[25].